{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:24Z","timestamp":1787027064388,"version":"build-2736575974"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hematological malignancies are the fifth most prevalent cancer category in developed countries, presenting significant treatment challenges. The side effects of chemotherapy and its non-selective nature have led researchers to explore combination therapies to enhance efficacy and improve patient outcomes. Parthenolide (PTL) emerges as a promising candidate, being the first small molecule identified for its selective action against leukemic stem cells. This article provides an overview of PTL\u2019s effects and its potential as a complementary treatment for hematological malignancies. A systematic search in PubMed, Scopus, Embase and Web of Science identified relevant studies using keywords and MeSH terms. Peer-reviewed studies examining PTL\u2019s mechanisms and therapeutic potential were included, while non-hematological studies and those lacking rigor were excluded. PTL targets key signaling pathways to combat malignancy, inhibiting NF-\u03baB and signal transducer and STAT3, promoting ROS production, and activating p53. These mechanisms contribute to its effectiveness in treating hematological malignancies. Approaches incorporating PTL or its derivatives show promise in increasing leukemic cell sensitivity to existing therapies and reducing resistance likelihood. Additionally, studies indicate that other drugs can synergistically enhance PTL\u2019s ability to eliminate leukemic cells. In conclusion, PTL represents a promising avenue for improving therapeutic outcomes in hematological malignancies, warranting further investigation into its mechanisms and potential in combination therapies.<\/jats:p>","DOI":"10.3389\/fphar.2025.1534686","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:22:26Z","timestamp":1744680146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Parthenolide: pioneering new frontiers in hematological malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Elmira","family":"Zarei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Omidkhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3324\/haematol.2014.115170","article-title":"Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants","volume":"100","author":"Agathanggelou","year":"2015","journal-title":"haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/b978-0-444-64056-7.00003-9","article-title":"The current and potential therapeutic uses of parthenolide","volume":"58","author":"Agatonovic-Kustrin","year":"2018","journal-title":"Stud. Nat. Prod. Chem."},{"key":"B3","first-page":"6091","volume-title":"Drug resistance in hematological malignancies. Int J Mol Sci","author":"Auberger","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.58209\/ijbc.14.3.57","article-title":"Plant-derived natural compounds as promising anticancer agents in hematological malignancies","volume":"14","author":"Bahmani","year":"2022","journal-title":"Iran. J. Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12195-015-0391-x","article-title":"Micelle delivery of parthenolide to acute myeloid leukemia cells","volume":"8","author":"Baranello","year":"2015","journal-title":"Cell. Mol. Bioeng."},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/cells11020196","article-title":"Super-enhancers dysregulations in hematological malignancies","volume":"11","author":"Belloucif","year":"2022","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2194","DOI":"10.1038\/cddis.2016.94","article-title":"Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis","volume":"7","author":"Carlisi","year":"2016","journal-title":"Cell death and Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e27918","DOI":"10.1097\/MD.0000000000027918","article-title":"Synergistic effects of herbal medicines and anticancer drugs: A protocol for systematic review and meta-analysis","volume":"100","author":"Cheon","year":"2021","journal-title":"Med. Baltim."},{"key":"B9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4161\/cbt.22952","article-title":"Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres","volume":"14","author":"Czyz","year":"2013","journal-title":"Cancer Biol. and Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1476-5381.2010.00749.x","article-title":"Cell context\u2010dependent activities of parthenolide in primary and metastatic melanoma cells","volume":"160","author":"Czyz","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2141.2010.08319.x","article-title":"The NF (Nuclear factor)-\u03baB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7\/JNK1-dependent apoptosis in human acute myeloid leukaemia cells","volume":"151","author":"Dai","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/molecules24112103","article-title":"Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia","volume":"24","author":"Darwish","year":"2019","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood cancer J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1182\/blood-2018-99-115996","article-title":"Combining parthenolide and sulfasalazine improves toxicity to CD200+ LIC populations in childhood ALL","volume":"132","author":"Diamanti","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1182\/blood.v126.23.2531.2531","article-title":"Combining BCL-2 inhibitors with parthenolide to treat childhood acute lymphoblastic leukaemia","volume":"126","author":"Diamanti","year":"2015","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/blood-2012-08-448852","article-title":"Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia","volume":"121","author":"Diamanti","year":"2013","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1080\/14756366.2018.1490734","article-title":"Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents","volume":"33","author":"Ding","year":"2018","journal-title":"J. Enzyme Inhibition Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3324\/haematol.2017.186700","article-title":"Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide","volume":"103","author":"Ede","year":"2018","journal-title":"haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1182\/blood.v128.22.4242.4242","article-title":"Parthenolide and DMAPT induce cell death in chronic myeloid leukemia cells via generation of reactive oxygen species","volume":"128","author":"Flores-L\u00f3pez","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1111\/jcmm.13755","article-title":"Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species","volume":"22","author":"Flores-Lopez","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1111\/jcmm.13755","article-title":"Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species","volume":"22","author":"Flores\u2010Lopez","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.lfs.2004.01.024","article-title":"Role of cysteine residues of p65\/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential","volume":"75","author":"Garcia-Pineres","year":"2004","journal-title":"Life Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.lfs.2004.01.024","article-title":"Role of cysteine residues of p65\/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential","volume":"75","author":"Garc\u00eda-Pi\u00f1eres","year":"2004","journal-title":"Life Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"39713","DOI":"10.1074\/jbc.m101985200","article-title":"Cysteine 38 in p65\/NF-\u03baB plays a crucial role in DNA binding inhibition by sesquiterpene lactones","volume":"276","author":"Garc\u0131\u0301a-Pi\u00f1eres","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bioorg.2019.03.056","article-title":"Design and synthesis of parthenolide-SAHA hybrids for intervention of drug-resistant acute myeloid leukemia","volume":"87","author":"Ge","year":"2019","journal-title":"Bioorg. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3109\/10428194.2011.555891","article-title":"The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma","volume":"52","author":"Gunn","year":"2011","journal-title":"Leukemia and lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2004-10-4135","article-title":"The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells","volume":"105","author":"Guzman","year":"2005","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1182\/blood-2010-04-278044","article-title":"Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways","volume":"116","author":"Hassane","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ijc.34243","article-title":"Therapy resistance mechanisms in hematological malignancies","volume":"152","author":"Hofmann","year":"2023","journal-title":"Int. J. cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","article-title":"Chemotherapy-induced peripheral neuropathies in hematological malignancies","volume":"121","author":"Jongen","year":"2015","journal-title":"J. neuro-oncology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beha.2006.10.005","article-title":"The leukemic stem cell","volume":"20","author":"Jordan","year":"2007","journal-title":"Best Pract. and Res. Clin. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.3390\/ijms24119167","article-title":"Parthenolide induces ROS-mediated apoptosis in lymphoid malignancies","volume":"24","author":"Jorge","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1016\/j.bmc.2015.05.037","article-title":"Synthesis and antileukemic activities of C1\u2013C10-modified parthenolide analogues","volume":"23","author":"Kempema","year":"2015","journal-title":"Bioorg. and Med. Chem."},{"key":"B40","first-page":"193","article-title":"Assessment of post chemotherapy complications among hematological malignancy patients","volume":"9","author":"Khalifa","year":"2021","journal-title":"Assiut Sci. Nurs. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/bjp.2008.319","article-title":"Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant\u2010derived sesquiterpene lactone compounds","volume":"155","author":"Kim","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2945.2945","volume-title":"Level of myeloperoxidase expression as a crucial determinant of sensitivity of myeloid leukemia cells to parthenolide-induced apoptosis","author":"Kim","year":""},{"key":"B43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11596-008-0508-8","article-title":"Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism","volume":"28","author":"Kong","year":"2008","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11596-015-1435-0","article-title":"Inhibitory effects of parthenolide on the activity of NF-\u03baB in multiple myeloma via targeting TRAF6","volume":"35","author":"Kong","year":"2015","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.22038\/ijbms.2020.40650.9610","article-title":"Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia\/lymphoma cells in vitro","volume":"23","author":"Kouhpaikar","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s1074-5521(01)00049-7","article-title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","volume":"8","author":"Kwok","year":"","journal-title":"Chem. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s1074-5521(01)00049-7","article-title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","volume":"8","author":"Kwok","year":"","journal-title":"Chem. and Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbrc.2014.11.102","article-title":"Parthenolide induces autophagy via the depletion of 4E-BP1","volume":"456","author":"Lan","year":"2015","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/abbs\/gmv019","article-title":"Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells","volume":"47","author":"Li","year":"2015","journal-title":"Acta biochimica biophysica Sinica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1039\/c9md00297a","article-title":"Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia","volume":"10","author":"Li","year":"2019","journal-title":"Medchemcomm"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/bph.14816","article-title":"Natural compounds as potential adjuvants to cancer therapy: preclinical evidence","volume":"177","author":"Lin","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/jpet.108.147934","article-title":"Modulation of DNA methylation by a sesquiterpene lactone parthenolide","volume":"329","author":"Liu","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.phymed.2015.05.006","article-title":"Widespread pain reliever profile of a flower extract of Tanacetum parthenium","volume":"22","author":"Mannelli","year":"2015","journal-title":"Phytomedicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.32725\/jab.2006.014","article-title":"Parthenolide has apoptotic and cytotoxic selective effect on B-chronic lymphocytic leukemia cells","volume":"4","author":"Marin","year":"2006","journal-title":"J. Appl. Biomed."},{"key":"B55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/rjim-2015-0004","article-title":"Acute lymphocytic leukemia in adults. Pathologic features and prognosis","volume":"53","author":"Marinescu","year":"2015","journal-title":"Romanian J. Intern. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1016\/j.pain.2013.08.002","article-title":"Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel","volume":"154","author":"Materazzi","year":"2013","journal-title":"Pain"},{"key":"B57","doi-asserted-by":"publisher","first-page":"188","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-3.15180","article-title":"Osteopontin siRNA does not confer resistance to toxic effects of parthenolide in Jurkat cells","volume":"42","author":"Mehri","year":"2020","journal-title":"Exp. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood.v118.21.2463.2463","article-title":"Molecular mechanisms of parthenolide-mediated pro-apoptotic activity in acute myeloid leukemia cells","volume":"118","author":"Minhajuddin","year":"2011","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur. J. cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lfs.2017.09.019","article-title":"Osteopontin plays a unique role in resistance of CD34+\/CD123+ human leukemia cell lines KG1a to parthenolide","volume":"189","author":"Mohammadi","year":"2017","journal-title":"Life Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1038\/onc.2013.565","article-title":"Mechanisms and consequences of constitutive NF-\u03baB activation in B-cell lymphoid malignancies","volume":"33","author":"Nagel","year":"2014","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ctrv.2010.02.016","article-title":"Molecular biology of breast cancer stem cells: potential clinical applications","volume":"36","author":"Nguyen","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"11707","DOI":"10.3390\/ijms252111707","article-title":"In vitro purging of acute lymphoblastic leukemia (B-all) cells with the use of PTL, DMAPT, or PU-H71","volume":"25","author":"Ortiz-Reyes","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.20517\/2572-8180.2018.07","article-title":"Synergistic activity of parthenolide and cytarabine in acute promyelocytic leukemia HL-60 cell line","volume":"3","author":"Papie\u017c","year":"2018","journal-title":"J. Unexplored Med. Data"},{"key":"B65","first-page":"5","article-title":"The role of oxidative stress in the cooperation of parthenolide and etoposide in HL-60 cells","volume":"60","author":"Papie\u017c","year":"2020","journal-title":"Folia Medica Cracoviensia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","article-title":"Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells","volume":"288","author":"Pei","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1074\/jbc.m116.750653","article-title":"Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells","volume":"291","author":"Pei","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/medicina55040110","article-title":"Synergistic effects of plant derivatives and conventional chemotherapeutic agents: an update on the cancer perspective","volume":"55","author":"Pezzani","year":"2019","journal-title":"Medicina"},{"key":"B69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood cancer J."},{"key":"B70","article-title":"Anticancer mechanism of parthenolide analogue PTLA-1 on adriamycin resistant human chronic myeloid leukemia cell line K562\/ADR","volume":"4","author":"Ren","year":"2022","journal-title":"Front. Med. Sci. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1703774","DOI":"10.1002\/smll.201703774","article-title":"Biodegradable, drug-loaded nanovectors via direct hydration as a new platform for cancer therapeutics","volume":"14","author":"Ridolfo","year":"2018","journal-title":"Small"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cancers3021605","article-title":"The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells","volume":"3","author":"Rushworth","year":"2011","journal-title":"Cancers"},{"key":"B73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/jrms.JRMS_960_17","article-title":"Chemotherapy-related infectious complications in patients with Hematologic malignancies","volume":"23","author":"Rusu","year":"2018","journal-title":"J. Res. Med. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.exphem.2013.04.012","article-title":"Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity","volume":"41","author":"Sen","year":"2013","journal-title":"Exp. Hematol."},{"key":"B75","first-page":"295","volume-title":"Chemotherapeutics","author":"Shields","year":"2017"},{"key":"B76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","article-title":"Targeting acute myeloid leukemia stem cell signaling by natural products","volume":"16","author":"Siveen","year":"2017","journal-title":"Mol. cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/bbrc.1999.1948","article-title":"Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family","volume":"267","author":"Sobota","year":"2000","journal-title":"Biochem. biophysical Res. Commun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/leu.2013.9","article-title":"Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide\u2019s anti-leukemic activity","volume":"27","author":"Spagnuolo","year":"2013","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/sj.leu.2404230","article-title":"The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro","volume":"20","author":"Steele","year":"2006","journal-title":"Leukemia"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1158\/1078-0432.CCR-07-1359","article-title":"Antimyeloma effects of a sesquiterpene lactone parthenolide","volume":"14","author":"Suvannasankha","year":"2008","journal-title":"Clin. cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/ph13080194","article-title":"Parthenolide as cooperating agent for anti-cancer treatment of various malignancies","volume":"13","author":"Sztiller-Sikorska","year":"2020","journal-title":"Pharmaceuticals"},{"key":"B82","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bioorg.2017.01.020","article-title":"Synthesis of dual-action parthenolide prodrugs as potent anticancer agents","volume":"71","author":"Taleghani","year":"2017","journal-title":"Bioorg. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/onc.2011.427","article-title":"NF-\u03baB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the \u03b2-catenin pathway","volume":"31","author":"Thu","year":"2012","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","first-page":"21126","DOI":"10.1002\/jcp.28715","article-title":"Modulation of Myb\u2010induced NF\u2010kB\u2010STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors","volume":"234","author":"Tian","year":"2019","journal-title":"J. Cell. physiology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdi042","article-title":"Home care versus hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia","volume":"16","author":"Van Tiel","year":"2005","journal-title":"Ann. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1182\/blood.v112.11.1708.1708","article-title":"The parthenolide derivative LC-1 is an effective single agent and is highly synergistic with existing therapies in multiple myeloma","volume":"112","author":"Walsby","year":"2008","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jbt.20411","article-title":"Combined effects of FLT3 and NF\u2010\u03baB selective inhibitors on acute myeloid leukemia in vivo","volume":"26","author":"Wang","year":"2012","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B88","first-page":"3106","article-title":"Parthenolide sensitizes HL-60 cells to aclarubicin-induced apoptosis by inhibiting NF-kappa band COX-2 activation","volume":"5","author":"Wang","year":"2011","journal-title":"J. Med. Plants Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s10495-006-0287-2","article-title":"Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity","volume":"11","author":"Wang","year":"2006","journal-title":"Apoptosis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/leu.2011.103","article-title":"p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies","volume":"25","author":"Wickremasinghe","year":"2011","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1073\/pnas.1002890107","article-title":"Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia","volume":"107","author":"Wu","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11427-015-4922-4","article-title":"Natural products against hematological malignancies and identification of their targets","volume":"58","author":"Xu","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejmech.2016.12.044","article-title":"Synthesis and anti-acute myeloid leukemia activity of C-14 modified parthenolide derivatives","volume":"127","author":"Yang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.7150\/jca.52641","article-title":"Suppression of aberrant activation of NF-\u03baB pathway in drug-resistant leukemia stem cells contributes to parthenolide-potentiated reversal of drug resistance in leukemia","volume":"12","author":"Yi","year":"2021","journal-title":"J. Cancer"},{"key":"B95","first-page":"82","article-title":"Parthenolide induces apoptosis in committed progenitor AML cell line U937 via reduction in osteopontin","volume":"4","author":"Zahedpanah","year":"2016","journal-title":"Rep. Biochem. and Mol. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/leu.2015.343","article-title":"In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche","volume":"30","author":"Zong","year":"2016","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2007.03.002","article-title":"Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells","volume":"254","author":"Zunino","year":"2007","journal-title":"Cancer Lett."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3892\/ijo_00000782","article-title":"Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t (4; 11)","volume":"37","author":"Zunino","year":"2010","journal-title":"Int. J. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:22:29Z","timestamp":1744680149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":98,"alternative-id":["10.3389\/fphar.2025.1534686"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1534686","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1534686"}}